Article info

Download PDFPDF

Original article
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Authors

  1. Correspondence to Professor Peter Nash; drpnash{at}tpg.com.au
View Full Text

Citation

Nash P, Behrens F, Orbai A, et al
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Publication history

  • Received April 1, 2018
  • Revision received June 29, 2018
  • Accepted July 6, 2018
  • First published September 7, 2018.
Online issue publication 
September 07, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.